Pfizer profits boost as demand for Covid-19 vaccine remains high           

While vaccine powered much of company's growth last year, its antiviral treatment Paxlovid, whose demand has surged in recent months, is expected to further bolster revenue

Pfizer has been banking on demand for vaccine boosters to drive up sales in the next few years.

Pfizer beat second-quarter profit expectations as its Covid-19 pill as well as vaccine remained in high demand following an uptick in infections in the US. 

Revenue from the antiviral pill, Paxlovid, exceeded market estimates by more than $1bn (€983m), while vaccine sales surged 20%, helping the drug maker reaffirm the combined 2022 revenue forecast of $54bn.